Plain-English translation of NCT07875582 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Pancreatic cancer is often diagnosed late, when treatment options are limited. This study is testing whether new protein markers in the blood—measured alongside the standard CA 19-9 test—can help doctors tell the difference between pancreatic cancer and other pancreatic conditions like chronic pancreatitis or benign cysts. Researchers hope that combining multiple blood markers will give a clearer, earlier picture of what's happening in the pancreas.
The current blood test used for pancreatic cancer (CA 19-9) isn't accurate enough, especially for catching cancer early or distinguishing it from benign conditions. This study aims to find better blood-based markers that could help doctors diagnose pancreatic disease more accurately and give patients the chance for earlier treatment.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will visit one of two medical centers in Romania where researchers will collect your medical history, review your imaging and lab results, and draw a blood sample for protein marker testing. The blood draw is a one-time event that happens before you start any cancer treatment. You may be asked follow-up questions about your health over time, but the main participation involves sharing your existing medical information and providing the blood sample.
AI-generated summary from trial data · Nov 10, 2026 · Not medical advice
Romania